BACKGROUND INFORMATION ON THE PROCEDURE 
1.1 
Submission of the dossier 
The applicant m e d a c Gesellschaft für klinische Spezialpräparate mbH submitted on 4 May 2006 an 
application  for  Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  through  the 
centralised procedure for Gliolan, which was designated as an orphan medicinal product EU/3/02/121 
on  13  November  2002.  Gliolan  was  designated  as  an  orphan  medicinal  product  in  the  following 
indication:  Intra-operative photodynamic diagnosis of residual glioma. The calculated prevalence of 
this condition was 1 in 10,000 in EU population. 
The applicant applied for the following indication visualisation of malignant tissue during surgery for 
malignant glioma.   
Protocol Assistance: 
The applicant received Protocol Assistance from the CHMP on 25 April 2003 and on 21 January 2005. 
The Protocol Assistance pertained to the clinical and quality aspects of the dossier respectively.  
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:   Cristina Sampaio 
Co-Rapporteur: Michal Pirozynski 
1.2 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 4 May 2006. 
The procedure started on 24 May 2006. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 22 August 
2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  
15 August 2007. 
During  the  meeting  on  18-21  September  2006  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 21 September 2006. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
22 December 2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 23 February and an update on 28 February 2007. 
During  the  CHMP  meeting  on  19-22  March  2007  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing by the applicant.  
The applicant submitted the responses to the CHMP consolidated list of outstanding issues and 
in preparation for the SAG Oncology meeting on 20 April 2007. 
The Rapporteurs circulated the updated Joint Assessment Report on the applicant’s responses to 
the CHMP on 4 May 2007. 
During  a  meeting  of  SAG  Oncology  on  11  May  2007,  experts  were  convened  to  address 
questions raised by the CHMP.  
During  the  CHMP  meeting  on  21-24  May  2007  the  CHMP  agreed  on  a  second  list  of 
outstanding issues to be addressed in writing by the applicant. 
The  applicant  submitted  the  responses  to  the  CHMP  second  consolidated  list  of  outstanding 
issues on 6 June 2007. 
  The  Rapporteurs  circulated  a  further  updated  Joint  Assessment  Report  on  the  applicant’s 
responses to the CHMP second list of outstanding issues on 13 June 2007. 
©EMEA 2007 
1/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
During  the  meeting  on  18-21  June 2007  the  CHMP, in  the light  of  the  overall data  submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Gliolan  on  21  June  2007.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 20 June 2007. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 7 September 2007. 
©EMEA 2007 
2/2 
 
 
 
